SCHEMBL8937263

SCHEMBL8937263

O=C(O)/C=C(\c1ccccc1)c1ccc2ccccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
MAPT P10636 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 2/20 0.51
EGFR P00533 1/20 0.51
TP53 P04637 1/20 0.51
CYP3A4 P08684 1/20 0.51
PKM P14618 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
ALOX12 P18054 1/20 0.51
JAK1 P23458 1/20 0.51
MAPK1 P28482 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD17B10 Q99714 1/20 0.51
PDPK1 O15530 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937260 1.00 CES2 (0.55) CES2CES1MEN1KMT2AMAPT
SCHEMBL8937266 1.00 CES2 (0.55) CES2CES1MEN1KMT2AMAPT
SCHEMBL63954 0.82 CES1 (0.50) CES2CES1MEN1KMT2AMAPT
Hydrochloric Acid SCHEMBL4398755 0.80 NFE2L2 (0.48) CES2CES1MEN1KMT2AMAPT
SCHEMBL9806330 0.79 CES2 (0.50) CES2CES1MEN1KMT2AMAPT
SCHEMBL9806335 0.79 CES2 (0.50) CES2CES1MEN1KMT2AMAPT
SCHEMBL6958568 0.79 TERT (0.59) CES2CES1MEN1KMT2AMAPT
SCHEMBL6958571 0.79 TERT (0.59) CES2CES1MEN1KMT2AMAPT
SCHEMBL6958575 0.79 TERT (0.59) CES2CES1MEN1KMT2AMAPT
SCHEMBL6691216 0.77 CA12 (0.53) CES2MEN1KMT2AMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5559109-A Method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma or shock by administering a PAF antagonist SANKKO COMPANY, LIMITED (JP) 1996-09-24 US disclosed
US-5556852-A PLATELET ACTIVATING FACTOR ANTAGONISTS SANKYO COMPANY, LIMITED (JP) 1996-09-17 US disclosed
EP-0395446-B1 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists SANKYO CO (JP) 1995-03-01 EP disclosed
US-5369106-A N-acryloylpiperazine derivatives, their preparation and their use of PAF antagonists SANKYO COMPANY, LIMITED (JP) 1994-11-29 US disclosed
US-5192766-A Platelet activating factor antagonist SANKYO COMPANY, LIMITED (JP) 1993-03-09 US disclosed
EP-0395446-A2 N-acryloylpiperazine derivatives, their preparation and their use as paf antagonists Sankyo Company Limited (JP) 1990-10-31 EP disclosed